Mounjaro®
Starting from £179.99/mo
Start journey Learn moreIf you take Wegovy and want to donate blood, the short answer is that most UK blood services ask donors to pause semaglutide — or wait a set period after their last dose — before donating. The decision ultimately rests with the blood service, not your prescriber, because the concern centres on the recipient rather than you. Wegovy is a prescription-only medicine for weight management, and any decision about continuing or pausing it should involve a clinician who knows your full picture.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Blood services screen donors partly to protect recipients. When a donor is on a prescription medicine, the question the blood service asks is whether any trace of that medicine in the donated blood could affect someone receiving a transfusion. With semaglutide (the active ingredient in Wegovy) there is no published evidence of harm to recipients, but NHSBT's standing policy is precautionary: medicines that are not licensed for use in all potential recipient groups (including pregnant women, children, and people with specific conditions) can trigger deferral periods.
This is different from a safety problem with Wegovy itself. The NHS medicines page for semaglutide covers its use and side-effect profile in detail, and nothing there relates to blood donation compatibility. The restriction, where it exists, is a supply-chain precaution on the recipient side.
Blood service guidance is also updated independently of prescribing guidance, so a rule that applied six months ago may have changed. The only reliable source is NHSBT's own donor eligibility tool or helpline. If you are in Scotland, Wales or Northern Ireland, the relevant national blood service may have slightly different rules, always check with them directly.
A question our prescribers hear most weeks is whether starting Wegovy means giving up blood donation entirely. The answer is no, but timing matters. NHSBT has historically applied a deferral period for donors taking medicines in certain pharmacological classes, meaning you would be asked to wait a specified period after your last dose before donating.
Because semaglutide has a relatively long half-life (roughly one week), a deferral measured in weeks rather than days is consistent with how similar medicines are handled. If you want a thorough look at how Wegovy and blood donation interact, including how deferral periods are typically applied to GLP-1 medicines, that page goes into the detail. The exact period NHSBT applies is theirs to confirm (it can shift when their clinical advisers review the evidence) so treat any figure you read on a forum or general article as a starting point, not the final word.
If you are considering starting Wegovy and blood donation is important to you, this is worth raising at the point of consultation. Pausing treatment temporarily to donate is medically possible, but it should be a planned decision, not an impromptu one. Stopping and restarting a GLP-1 medicine can involve re-titration from a lower dose, which your prescriber would manage. Read more about what Wegovy treatment involves on the semaglutide overview page.
The practical decision has two parts. First, check with NHSBT (or your national blood service) whether your current dose and timing makes you eligible today. Second, if they say you need to pause, speak to your prescriber before stopping Wegovy (even briefly) because pausing a weight-management medicine without clinical input can disrupt your treatment plan more than people expect.
It is also worth knowing that blood donation eligibility covers a wider picture than just medication. Your haemoglobin level, recent travel, and general health all factor in. The blood service will screen these at the session regardless.
If you are also thinking about how Wegovy interacts with other medicines or circumstances, the page on Wegovy and blood thinners covers a related clinical question. For practical aspects of managing your medicine day-to-day, the guidance on travelling with Wegovy is useful reading.
The MHRA's Yellow Card scheme is the right route if you ever suspect an unexpected reaction, it is available at yellowcard.mhra.gov.uk. For questions specific to your treatment, our prescribers are available seven days a week via aftercare once you are a patient.
Some people researching blood donation on Wegovy are also at the early stage of deciding whether to start treatment. Our dedicated page on whether you can donate blood while on Wegovy is a good first read if that question is what brought you here. If price is part of that calculation, the Wegovy cost page sets out what UK private pricing actually looks like and what a legitimate prescription service includes, worth reading before comparing headline figures across providers.
If you are ready to explore whether Wegovy is clinically appropriate for you, speak to our prescribers through a free consultation. A named clinician reviews every submission (not a piece of software) and your consultation is handled the same day.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.